All Stories

  1. Family History of Diabetes and Clinical Characteristics in Children at Diagnosis of Type 1 Diabetes—A Swedish Population-Based Study
  2. Sex-Specific Cytokine, Chemokine, and Growth Factor Signatures in T1D Patients and Progressors
  3. Physical activity, sedentary behaviour, and childhood asthma: a European collaborative analysis
  4. HbA1c and the risk of developing peripheral neuropathy in childhood‐onset type 1 diabetes: A follow‐up study over 3 decades
  5. Time spent outdoors in childhood related to myopia among young adults in the Swedish ABIS cohort
  6. Also the parents of children with type 1 diabetes need psychological support
  7. Prevalence and Predictive Factors for Celiac Disease in Children With Type 1 Diabetes: Whom and When to Screen? A Nationwide Longitudinal Cohort Study of Swedish Children
  8. Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts
  9. Immune Interventions at Onset of Type 1 Diabetes — Finally, a Bit of Hope
  10. Prenatal exposure to environmental contaminants is associated with altered cord serum metabolite profiles in future immune-mediated diseases
  11. Sex Differences in Age of Diagnosis, HLA Genotype, and Autoantibody Profile in Children With Type 1 Diabetes
  12. Cumulative incidence of type 1 diabetes in two cohorts of children with different national gluten recommendations in infancy
  13. A 1‐year pilot study of intralymphatic injections of GAD‐alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes
  14. Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study
  15. Cord serum metabolic signatures of future progression to immune-mediated diseases
  16. Severe COVID-19 Infection in Type 1 and Type 2 Diabetes During the First Three Waves in Sweden
  17. Childhood sleep and obesity risk: A prospective cohort study of 10 000 Swedish children
  18. Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic ...
  19. Infections in the first year of life and development of beta cell autoimmunity and clinical type 1 diabetes in high-risk individuals: the TRIGR cohort
  20. Month of birth and the risk of developing type 1 diabetes among children in the Swedish national Better Diabetes Diagnosis Study
  21. Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes
  22. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
  23. Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes
  24. Breastfeeding and cortisol in hair in children
  25. Infections and antibiotics during fetal life and childhood and their relationship to juvenile idiopathic arthritis: a prospective cohort study
  26. Increasing plasma glucose before the development of type 1 diabetes—the TRIGR study
  27. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
  28. Combined Etanercept, GAD‐alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes
  29. Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk
  30. Breastfeeding and Stress in Children
  31. Effect of COVID‐19 pandemic on treatment of Type 1 diabetes in children
  32. Association between family history, early growth and the risk of beta cell autoimmunity in children at risk for type 1 diabetes
  33. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
  34. Combined Vitamin D, Ibuprofen and Glutamic Acid decarboxylase-alum Treatment in Recent Onset Type I Diabetes: Lessons from the DIABGAD Randomized Pilot Trial
  35. Abdominal Pain in Children Develops With Age and Increases With Psychosocial Factors
  36. No acute pancreatitis but reduced exocrine pancreatic function at diagnosis of type 1 diabetes in children
  37. The jury is still out on possible links between cows’ milk and type 1 diabetes
  38. Impact of Age of Onset, Puberty, and Glycemic Control Followed From Diagnosis on Incidence of Retinopathy in Type 1 Diabetes: The VISS Study
  39. Pet exposure in the family during pregnancy and risk for type 1 diabetes-The prospective ABIS study
  40. Beta cell function after intensive subcutaneous insulin therapy or intravenous insulin infusion at onset of type 1 diabetes in children without ketoacidosis
  41. Insulin-Like Growth Factor-1 at Diagnosis and during Subsequent Years in Adolescents with Type 1 Diabetes
  42. Intralymphatic therapy of Type 1 diabetes
  43. It is time to restore Rules for Authorship of scientific publications
  44. Increasing Incidence but Decreasing Awareness of Type 1 Diabetes in Sweden
  45. GAD65: a prospective vaccine for treating Type 1 diabetes?
  46. Worm infestations and development of autoimmunity in children – The ABIS study
  47. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients
  48. Intralymphatic Injection of Autoantigen in Type 1 Diabetes
  49. Yngve Larsson (1917-2014), a pioneer in the treatment of childhood diabetes
  50. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis
  51. The clinical potential of low-level C-peptide secretion
  52. Reduced brachial artery distensibility in patients with type 1 diabetes
  53. Physical Activity, Blood Glucose and C-Peptide in Healthy School-Children, a Longitudinal Study
  54. Author’s Reply to Dayal: “Therapies to Preserve β-Cell Function in Type 1 Diabetes”
  55. Impact of Low Maternal Education on Early Childhood Overweight and Obesity in Europe
  56. No association between use of multivitamin supplement containing vitamin D during pregnancy and risk of Type 1 Diabetes in the child
  57. High cortisol in 5-year-old children causes loss of DNA methylation in SINE retrotransposons: a possible role for ZNF263 in stress-related diseases
  58. Pedometer-determined physical activity level and change in arterial stiffness in Type 2 diabetes over 4 years
  59. Response to Comment on Nordwall et al. Impact of HbA1c, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 2015;38:308–315
  60. Early Psychosocial Exposures, Hair Cortisol Levels, and Disease Risk
  61. Mother's education and the risk of preterm and small for gestational age birth: a DRIVERS meta-analysis of 12 European cohorts
  62. High physical activity in young children suggests positive effects by altering autoantigen‐induced immune activity
  63. Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study
  64. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers
  65. BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children
  66. Impact of HbA1c, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden)
  67. Detection of a Low-Grade Enteroviral Infection in the Islets of Langerhans of Living Patients Newly Diagnosed With Type 1 Diabetes
  68. Phases of type 1 diabetes in children and adolescents
  69. Children’s Views on Long-Term Screening for Type 1 Diabetes
  70. Infectious Disease at Gluten Introduction and Risk of Childhood Diabetes Mellitus
  71. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months
  72. Breast-feeding Duration and Gluten Introduction Among Mothers With Celiac Disease
  73. Hydrolyzed Infant Formula and Early β-Cell Autoimmunity
  74. Preterm birth, infant weight gain, and childhood asthma risk: A meta-analysis of 147,000 European children
  75. Combination therapy for preservation of beta cell function in Type 1 diabetes: New attitudes and strategies are needed!
  76. Antibiotic exposure in pregnancy and risk of coeliac disease in offspring: a cohort study
  77. High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus
  78. Risk of renal disease in patients with both type 1 diabetes and coeliac disease
  79. Psychological Stress in Children May Alter the Immune Response
  80. Antibodies to Influenza Virus A/H1N1 Hemagglutinin in Type 1 Diabetes Children Diagnosed Before, During and After the SWEDISH A(H1N1)pdm09 Vaccination Campaign 2009-2010
  81. Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B1 and Type 1 Diabetes
  82. Variability in the CIITA gene interacts with HLA in multiple sclerosis
  83. Is it time to challenge the established theories surrounding type 1 diabetes?
  84. Guidelines on the use of extracorporeal photopheresis
  85. Expression pattern of T-helper 17 cell signaling pathway and mucosal inflammation in celiac disease
  86. The latest pharmacotherapy options for type 1 diabetes
  87. Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195–201
  88. Recruitment and retention of participants for an international type 1 diabetes prevention trial: A coordinators’ perspective
  89. Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitus negative for other islet cell antibodies
  90. Maternal Influence on Child HPA Axis: A Prospective Study of Cortisol Levels in Hair
  91. Age‐dependent decline of β‐cell function in type 1 diabetes after diagnosis: a multi‐centre longitudinal study
  92. Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
  93. Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
  94. General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes
  95. Early Electrophysiological Abnormalities and Clinical Neuropathy
  96. Use of a Web 2.0 Portal to Improve Education and Communication in Young Patients With Families: Randomized Controlled Trial
  97. Low C-peptide levels and decreased expression of TNF and CD45 in children with high risk of type 1 diabetes
  98. Behavioral Science Research Informs Bioethical Issues in the Conduct of Large-Scale Studies of Children's Disease Risk
  99. Psychometric properties of the Pediatric Testing Attitudes Scale-Diabetes (P-TAS-D) for parents of children undergoing predictive risk screening
  100. Long-term coeliac disease influences risk of death in patients with type 1 diabetes
  101. Thyroid autoimmunity in relation to islet autoantibodies and HLA-DQ genotype in newly diagnosed type 1 diabetes in children and adolescents
  102. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents
  103. Family psychological stress early in life and development of type 1 diabetes: The ABIS prospective study
  104. Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes
  105. Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes
  106. A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes
  107. Higher maternal education is associated with favourable growth of young children in different countries
  108. Immune Intervention in Type I Diabetes Mellitus
  109. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
  110. Does modern high standard life style cause type 1 diabetes in children?
  111. Serum adipokines as biomarkers of beta‐cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin
  112. A Population-Based Study of the Risk of Diabetic Retinopathy in Patients With Type 1 Diabetes and Celiac Disease
  113. Lessons From the Mixed-Meal Tolerance Test
  114. Residual beta cell function at diagnosis of type 1 diabetes in children and adolescents varies with gender and season
  115. C-peptide in diabetes diagnosis and therapy
  116. Breast-Feeding and Childhood-Onset Type 1 Diabetes
  117. Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes
  118. Decreased GAD65‐specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD‐alum
  119. Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes
  120. Pedometer‐determined physical activity is linked to low systemic inflammation and low arterial stiffness in Type 2 diabetes
  121. Zinc Transporter 8 Autoantibodies and Their Association With SLC30A8 and HLA-DQ Genes Differ Between Immigrant and Swedish Patients With Newly Diagnosed Type 1 Diabetes in the Better Diabetes Diagnosis Study
  122. The influence of structure, process, and policy on HbA1c levels in treatment of children and adolescents with type 1 diabetes
  123. HTR1A a Novel Type 1 Diabetes Susceptibility Gene on Chromosome 5p13-q13
  124. Early human enterovirus infections in healthy Swedish children participating in the PRODIA pilot study
  125. The viral aetiology of diabetes: a tribute to Keith Taylor (1929-2012)
  126. Interbirth Interval Is Associated With Childhood Type 1 Diabetes Risk
  127. Could the social environment trigger the induction of diabetes related autoantibodies in young children?
  128. GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus
  129. Growth differences between North American and European children at risk for type 1 diabetes
  130. Adaptive and Innate Immune Responsiveness toBorrelia burgdorferi sensu latoin Exposed Asymptomatic Children and Children with Previous Clinical Lyme Borreliosis
  131. Are drug treatments for psoriasis a cardiovascular risk?
  132. In light of recent clinical trial results, what lies next for Type 1 diabetes vaccine research?
  133. Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
  134. Cortisol in hair measured in young adults - a biomarker of major life stressors?
  135. C-peptide in the classification of diabetes in children and adolescents
  136. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
  137. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
  138. Low risk HLA-DQ and increased body mass index in newly diagnosed type 1 diabetes children in the Better Diabetes Diagnosis study in Sweden
  139. Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children
  140. Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes
  141. The effect of gluten-free diet on Th1–Th2–Th3-associated intestinal immune responses in celiac disease
  142. Feasibility and compliance in a nutritional primary prevention trial in infants at increased risk for type 1 diabetes
  143. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients
  144. Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies
  145. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
  146. Type 1 diabetes patients born to immigrants to Sweden increase their native diabetes risk and differ from Swedish patients in HLA types and islet autoantibodies
  147. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response
  148. Early induction of GAD65‐reactive Th2 response in type 1 diabetic children treated with alum‐formulated GAD65
  149. Seroprevalence of Borrelia IgG antibodies among young Swedish children in relation to reported tick bites, symptoms and previous treatment for Lyme borreliosis: a population-based survey
  150. Immune Intervention in Children with Type 1 Diabetes
  151. Overweight and obesity in infants and pre-school children in the European Union: a review of existing data
  152. GAD-alum (Diamyd) – a new concept for preservation of residual insulin secretion
  153. Infectious Disease and Risk of Later Celiac Disease in Childhood
  154. Parents' Psychological Stress Over Time may Affect Children's Cortisol at Age 8
  155. Maternal Age at Birth and Childhood Type 1 Diabetes: A Pooled Analysis of 30 Observational Studies
  156. C‐peptide an adequate endpoint in type 1 diabetes
  157. Daily vegetable intake during pregnancy negatively associated to islet autoimmunity in the offspring-The ABIS study
  158. Health-related quality of life in intensively treated young patients with type 1 diabetes
  159. Practical matters, rather than lack of trust, motivate non-participation in a long-term cohort trial
  160. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes
  161. Therapy with GAD in diabetes
  162. The non‐inherited maternal HLA haplotype affects the risk for type 1 diabetes
  163. Twenty years experiences of interprofessional education in Linköping – ground-breaking and sustainable
  164. Relationship of food frequencies as reported by parents to overweight and obesity at 5 years
  165. An indirect competitive immunoassay for insulin autoantibodies based on surface plasmon resonance
  166. Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children
  167. Psychological Stress and Obesity
  168. Tobacco Exposure and Diabetes‐Related Autoantibodies in Children
  169. Web 2.0 systems supporting childhood chronic disease management: A pattern language representation of a general architecture
  170. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity
  171. Parent perceptions of child sleep: a study of 10 000 Swedish children
  172. GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
  173. Exclusive breastfeeding of Swedish children and its possible influence on the development of obesity: a prospective cohort study
  174. Web 2.0 Systems Supporting Childhood Chronic Disease Management: Design Guidelines Based on Information Behaviour and Social Learning Theories
  175. Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
  176. Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk
  177. No evidence for activation of TH1 or TH17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
  178. Impaired CD4+ and CD8+ T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children
  179. Effect of HLA Genotype or CTLA‐4 Polymorphism on Cytokine Response in Healthy Children
  180. Do high blood glucose peaks contribute to higher HbA1c? Results from repeated continuous glucose measurements in children
  181. Detection of global glycosylation changes of serum proteins in type 1 diabetes using a lectin panel and multivariate data analysis
  182. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years
  183. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries
  184. Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes
  185. Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children
  186. Progression to type 1 diabetes and autoantibody positivity in relation to HLA-risk genotypes in children participating in the ABIS study
  187. Type 1 diabetes: increased height and weight gains in early childhood
  188. A1C in Children and Adolescents With Diabetes in Relation to Certain Clinical Parameters
  189. Adverse health effects related to tobacco smoke exposure in a cohort of three‐year olds
  190. Autoantibodies to IA-2β improve diabetes risk assessment in high-risk relatives
  191. Insulin Resistance and Progression to Type 1 Diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)
  192. Secular trends of pedometer‐determined physical activity in Swedish school children
  193. Immune intervention at diagnosis ? should we treat children to preserve beta-cell function?
  194. The importance of CTLA-4 polymorphism and human leukocyte antigen genotype for the induction of diabetes-associated cytokine response in healthy school children
  195. Risk factors in childhood obesity—findings from the All Babies In Southeast Sweden (ABIS) cohort
  196. IA-2 autoantibodies in incident type I diabetes patients are associated with a polyadenylation signal polymorphism in GIMAP5
  197. SUMO4 M55V polymorphism affects susceptibility to type I diabetes in HLA DR3- and DR4-positive Swedish patients
  198. Fasting plasma glucose levels in healthy preschool children: effects of weight and lifestyle
  199. Concern, pressure and lack of knowledge affect choice of not wanting to know high-risk status
  200. The Särimner Diabetes Simulator—A Look in the Rear View Mirror
  201. Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study
  202. Socio-economic determinants, maternal smoking and coffee consumption, and exclusive breastfeeding in 10 205 children
  203. Introduction and overview
  204. Inflammatory bowel disease in mother or father and neonatal outcome
  205. Milk consumption during pregnancy and infant birthweight
  206. Predictors and dietary consequences of frequent intake of high-sugar, low-nutrient foods in 1-year-old children participating in the ABIS study
  207. Short duration of breast-feeding as a risk-factor for β-cell autoantibodies in 5-year-old children from the general population
  208. Two Insulin Gene Single Nucleotide Polymorphisms Associated with Type 1 Diabetes Risk in the Finnish and Swedish Populations
  209. Celiac Disease and Risk of Subsequent Type 1 Diabetes
  210. Probiotics for the Prevention of Beta Cell Autoimmunity in Children at Genetic Risk of Type 1 Diabetes—the PRODIA Study
  211. Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents
  212. Higher prevalence of autoantibodies to insulin and GAD65 in Swedish compared to Lithuanian children with type 1 diabetes
  213. Importin beta: A novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage
  214. Quality of care from the patient's perspective in pediatric diabetes care
  215. Decreased In Vitro Type 1 Immune Response Against Coxsackie Virus B4 in Children With Type 1 Diabetes
  216. Nicotinamide Reduces High Secretion of IFN-γ in High-Risk Relatives Even Though It Does Not Prevent Type 1 Diabetes
  217. Coeliac disease and risk of renal disease—a general population cohort study
  218. Diminished IFN‐γ response to diabetes‐associated autoantigens in children at diagnosis and during follow up of type 1 diabetes
  219. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk
  220. Dietary risk factors for the emergence of type 1 diabetes-related autoantibodies in 2½-year-old Swedish children
  221. Early Diabetic Complications in a Population of Young Patients with Type 1 Diabetes Mellitus Despite Intensive Treatment
  222. Psychological Stress and the Risk of Diabetes-Related Autoimmunity: A Review Article
  223. Environmental factors related to the induction of beta-cell autoantibodies in 1-yr-old healthy children
  224. How to handle informed consent in longitudinal studies when participants have a limited understanding of the study
  225. Breastfeeding and introduction of solid foods in Swedish infants: the All Babies in Southeast Sweden study
  226. Assessment of Smoking Behaviors in the Home and Their Influence on Children's Passive Smoking: Development of a Questionnaire
  227. Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation
  228. Exclusive breastfeeding and risk of atopic dermatitis in some 8300 infants
  229. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study
  230. EEG abnormalities with and without relation to severe hypoglycaemia in adolescents with type 1 diabetes
  231. Parental smoking and risk of coeliac disease in offspring
  232. Psychological Stress May Induce Diabetes-Related Autoimmunity in Infancy
  233. Diminished Th1‐Like Response to Autoantigens in Children with a High Risk of Developing Type 1 Diabetes
  234. Aberrant regulation of interleukin‐12 receptor β2 chain on type 1 cytokine‐stimulated T lymphocytes in type 1 diabetes
  235. Socio-economic characteristics in children with coeliac disease
  236. Information and informed consent in a longitudinal screening involving children: a questionnaire survey
  237. Mothers' Attachment Insecurity and Diabetes‐Related Autoantibodies in Their Infants
  238. Poor In Vitro Maturation and Pro‐Inflammatory Cytokine Response of Dendritic Cells in Children at Genetic Risk of Type 1 Diabetes
  239. Milk consumption during pregnancy and infant birthweight
  240. Effect of Photopheresis on Lymphocyte Population in Children with Newly Diagnosed Type 1 Diabetes
  241. Parents' attitudes to children's tobacco smoke exposure and how the issue is handled in health care
  242. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes—the Linköping Diabetes Complications Study
  243. P1106 SOCIOECONOMIC DETERMINANTS, MATERNAL SMOKING, COFFEE CONSUMPTION AND EXCLUSIVE BREASTFEEDING IN 10 205 CHILDREN
  244. Future Intervention Trials in Type 1 Diabetes
  245. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes
  246. Psychosocial correlates of parenting stress, lack of support and lack of confidence/security
  247. Symptoms and Signs Have Changed in Swedish Children With Coeliac Disease
  248. The concentrations of short‐chain fatty acids and other microflora‐associated characteristics in faeces from children with newly diagnosed Type 1 diabetes and control children and their family members
  249. Induction of Diabetes‐Related Autoantibodies below Cutoff for “Positivity” in Young Nondiabetic Children
  250. Inheritance of MHC Class II Genes in Lithuanian Families with Type 1 Diabetes
  251. Vaccinations May Induce Diabetes‐Related Autoantibodies in One‐Year‐Old Children
  252. Continuous Subcutaneous Glucose Monitoring Improved Metabolic Control in Pediatric Patients With Type 1 Diabetes: A Controlled Crossover Study
  253. When does exposure of children to tobacco smoke become child abuse?
  254. A follow-up of medical graduates of a problem-based learning curriculum
  255. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes
  256. Continuous Monitoring of the Subcutaneous Glucose Level in Freely Moving Normal and Diabetic Rats and in Humans with Type 1 Diabetes
  257. Attitudes to bioethical issues: a case study of a screening project
  258. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety
  259. Severity at onset of childhood type 1 diabetes in countries with high and low incidence of the condition
  260. Inflammatory bowel disease in mother or father and neonatal outcome
  261. Screening for prediabetes in the general child population: maternal attitude to participation
  262. Cows' milk proteins cause similar Th1- and Th2-like immune response in diabetic and healthy children
  263. Coeliac disease in the father affects the newborn
  264. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial
  265. Tissue Transglutaminase Auto-antibodies in Cord Blood from Children to Become Celiacs
  266. Nerve conduction defects are retarded by tight metabolic control in type I diabetes
  267. Seasonal Variation of Birth Month and Breastfeeding in Children with Diabetes Mellitus
  268. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study
  269. Population-based screening for pre-diabetes in children may be conceived as reassuring
  270. Th1-like dominance in high-risk first-degree relatives of Type I diabetic patients
  271. The ABBOS-peptide from bovine serum albumin causes an IFN-γ and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes
  272. Seasonal Variation of HbA1c in Intensive Treatment of Children with Type 1 Diabetes
  273. Osteopontin is an autoantigen of the somatostatin cells in human islets: identification by screening random peptide libraries with sera of patients with insulin-dependent diabetes mellitus
  274. Month of birth and risk of developing insulin dependent diabetes in south east Sweden
  275. Previous Exposure to Measles, Mumps, and Rubella—but Not Vaccination During Adolescence—Correlates to the Prevalence of Pancreatic and Thyroid Autoantibodies
  276. Adverse events in intensively treated children and adolescents with type 1 diabetes
  277. Introduction and overview
  278. Unchanged incidence of severe retinopathy in a population of Type 1 diabetic patients with marked reduction of nephropathy
  279. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial
  280. Autonomic function in children with Type 1 diabetes mellitus
  281. Determination of mRNA expression for IFN-γ and IL-4 in lymphocytes from children with IDDM by RT-PCR technique
  282. Islet cell surface antibodies (ICSA) do bind to human pancreas: computerised, quantitative determination of ICSA using both pre- and postembedding immunocolloidal techniques
  283. Hypoglycaemia During Intensified Insulin Therapy of Children and Adolescents
  284. Severe Hypoglycemia in Children With IDDM: A prospective population study, 1992–1994
  285. Unchanged Insulin Absorption After 4 Days' Use of Subcutaneous Indwelling Catheters for Insulin Injections
  286. No acute effect of high blood glucose on nerve conduction in adolescents with IDDM
  287. Prevalence of diabetic retinopathy in children and adolescents with IDDM
  288. Psychological reactions at the onset of insulin‐dependent diabetes mellitus in children and later adjustment and metabolic control
  289. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.
  290. Glycemic Control and Prognosis in Type I Diabetic Patients With Microalbuminuria
  291. Normal values of nerve conduction in children and adolescents
  292. Psychological Stress and the Onset of IDDM in Children: A case-control study
  293. Adult cancer risks among the mothers of children with cancer
  294. Subclinical nerve dysfunction in children and adolescents with IDDM
  295. T Cell Proliferative Responses to Glutamic Acid Decarboxylase-65 in IDDM are Negatively Associated with HLA DR3/4
  296. Islet cell antibodies (ICA), insulin autoantibodies (IAA), islet cell surface antibodies (ICSA) and C-peptide in 1031 school children in a population with a high background incidence of IDDM
  297. Acute myeloid leukemia (AML-M1) with multiple trisomies and t(8;21)(q22;q22)
  298. Indications for a more aggressive disease process in newly diagnosed insulin-dependent diabetic children in Northern than in Southern Europe
  299. A high weight gain early in life is associated with an increased risk of Type 1 (insulin-dependent) diabetes mellitus
  300. Breast-feeding seems to play a marginal role in the prevention of insulin-dependent diabetes mellitus
  301. Prevalence and clinical picture of IDDM in Nigerian Igbo schoolchildren
  302. Särimner: a computer model of diabetes physiology for education of physicians and patients
  303. Relating homology between the Epstein-Barr virus BOLF1 molecule and HLA-DQw8 ? chain to recent onset Type 1 (insulin-dependent) diabetes mellitus
  304. HLA Heterozygosity in Insulin‐Dependent Diabetes is Most Frequent at the DQ Locus
  305. Islet cell surface antibodies preferentially inhibit glucose-stimulated insulin release in vitro
  306. Seasonality of Type 1 (insulin-dependent) diabetes mellitus: values of C-peptide, insulin antibodies and haemoglobin A1c show evidence of a more rapid loss of insulin secretion in epidemic patients
  307. Insulin, Love and Care
  308. No Cyclosporin A to Diabetic Children
  309. Cyclosporine in diabetes mellitus
  310. Family interaction and metabolic balance in juvenile diabetes mellitus
  311. Asthma and family interaction.
  312. Radiation in Dwellings and Cancer in Children
  313. MATERNAL SMOKING DURING PREGNANCY AND THE RISK OF CHILDHOOD CANCER
  314. MATERNAL SMOKING DURING PREGNANCY AND RISK OF CHILDHOOD CANCER
  315. HLA-DR 3 is associated with a more slowly progressive form of Type 1 (insulin-dependent) diabetes
  316. A two-colour immunofluorescence test with a monoclonal human proinsulin antibody improves the assay for islet cell antibodies
  317. Home Blood Glucose Monitoring in Diabetic Children and Adolescents
  318. Blood-retinal barriers in juvenile diabetics in relation to early clinical manifestations, HLA-DR types, and metabolic control
  319. Human Lymphocyte Antigen DR Types in Relation to Early Clinical Manifestations in Diabetic Children
  320. A Prospective Analysis of Islet-cell Cytotoxic Antibodies in Insulin-dependent Diabetic Children: Transient Effects of Plasmapheresis
  321. HLA-D region β-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin-dependent diabetic individuals
  322. Haptoglobin concentrations in children aged 9–10 years and its correlation to indirect parameters of erythrocyte turnover
  323. Plasma and urine carnitine in children with diabetes mellitus
  324. Abnormal proinsulin/c-peptide ratio in juvenile diabetes
  325. Rapid and slow rate of decrease in HbA1a + band HbA1cduring improved glycaemic control
  326. A prospective analysis of antibodies reacting with pancreatic islet cells in insulin-dependent diabetic children
  327. The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin
  328. SENSORY NERVE CONDUCTION VELOCITY AND VIBRATORY SENSIBILITY IN JUVENILE DIABETICS
  329. Beta-cell Function in Children with Diabetes
  330. Vitamin C as a Preventive Medicine against Common Colds in Children
  331. Prophylaxis of Migraine in Children
  332. C‐PEPTIDE IN JUVENILE DIABETICS BEYOND THE POSTINITIAL REMISSION PERIOD Relation to Clinical Manifestations at Onset of Diabetes, Remission and Diabetic Control
  333. HLA-types, C-peptide and insulin antibodies in juvenile diabetes
  334. C-Peptide in children with juvenile diabetes
  335. PROPRANOLOL IN TREATMENT OF MIGRAINE IN CHILDREN
  336. Section 11: ECP in Diabetes Mellitus